Shaji Kumar
María-Victoria Mateos
Rakesh PopatHow to transition patients to community-based bispecific antibody therapy
The Multiple Myeloma Hub spoke with Shaji Kumar, Mayo Clinic, Rochester, US. We asked about transitioning patients to community-based bispecific antibody therapy.
All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
TRANSLATE
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by AbbVie, Roche, Bristol Myers Squibb, Pfizer, GSK, Johnson & Johnson, Legend Biotech and Caribou Biosciences. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account to access:
Bookmark & personalize site content
Receive alerts for new content in your areas of interest
View multiple myeloma content recommended for you
Masterclass | Treating MM in the community: Bispecific antibodies
The delivery of bispecific antibody therapy for multiple myeloma in outpatient and community settings requires consideration of patient selection, care coordination, monitoring, and the management of treatment-associated toxicities.
The Multiple Myeloma Hub spoke with Shaji Kumar, Rakesh Popat, and María-Victoria Mateos about practical considerations for implementing bispecific antibody therapy in outpatient and community settings, including transitioning patients to community-based care, approaches to outpatient treatment delivery, and the monitoring and management of associated toxicities.
How to optimize outpatient delivery of bispecific antibody therapy for MM
The Multiple Myeloma Hub spoke with Rakesh Popat, UCL Hospitals NHS Foundation Trust, London, UK. We asked how to optimize outpatient delivery of bispecific antibody therapy for multiple myeloma.
How to manage toxicities associated with bispecific antibody therapy for MM in community practice
The Multiple Myeloma Hub spoke with María-Victoria Mateos, University Hospital of Salamanca, ES. We asked about the management of toxicities associated with bispecific antibody therapy for multiple myeloma in community practice.
This educational resource is independently supported by Johnson & Johnson. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
Regarding bispecific antibodies for multiple myeloma, which of the following AE mitigation strategies do you use most routinely in your practice?